134,207 Shares in AtriCure, Inc. $ATRC Acquired by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 134,207 shares of the medical device company’s stock, valued at approximately $3,755,000. Rice Hall James & Associates LLC owned about 0.26% of AtriCure at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Assenagon Asset Management S.A. acquired a new position in shares of AtriCure in the 2nd quarter valued at $1,744,000. F m Investments LLC acquired a new stake in AtriCure during the 4th quarter worth about $2,872,000. Vanguard Group Inc. lifted its position in AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after acquiring an additional 62,861 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in AtriCure during the 1st quarter valued at about $7,922,000. Finally, California State Teachers Retirement System grew its stake in AtriCure by 33.3% during the 1st quarter. California State Teachers Retirement System now owns 59,947 shares of the medical device company’s stock valued at $1,710,000 after purchasing an additional 14,987 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Insider Activity

In related news, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the sale, the director owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Maggie Yuen sold 3,500 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. This represents a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 47,246 shares of company stock worth $1,777,845. Insiders own 4.00% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ATRC. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group lifted their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

AtriCure Stock Performance

NASDAQ ATRC opened at $44.77 on Tuesday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of 213.20 and a beta of 1.20. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $45.86. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The stock has a 50-day moving average of $34.27 and a 200 day moving average of $31.52.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.